The adoption of healthcare IT leads as the main driver of growth.
The population health management market size is expected to grow by $11.89 billion from 2020 to 2025, according to a market forecast report done by Technavio, a global technology research and advisory company.
Some of the primary growth drivers for the population health management market are the adoption of healthcare IT, increasing number of specialty and multi-chain hospitals, and growing incidence of chronic disorders, according to Technavio. However, factors such as rising cost of installation of population health management platforms may challenge market growth.
Data shared market segmentation highlights in the report were the population health management market being segmented by component into software and services and the software segment has experienced significant market share growth.
In addition, the regional analysis of the report shared the population health management market was segmented into five regions, namely North America, Europe, APAC, MEA, and South America. In those regions, 59% of the growth is expected to originate from North America. Other findings state the U.S. and Canada are the key countries for the population health management market in North America. Lastly, the report indicates that an increasing number of specialty and multi-chain hospitals will drive the population health management market growth in North America during the forecast period.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More